Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.47 |
| ▸ | CCR5 | P51681 | 2/20 | 0.47 |
| ▸ | CCR8 | P51685 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.38 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21886187 | 0.78 | CCR1 (0.45) | CCR1CCR5CCR8CYP1A2PIK3CB | |
| SCHEMBL13538215 | 0.78 | CCR1 (0.45) | CCR1CCR5CCR8CYP1A2PIK3CB | |
| SCHEMBL858999 | 0.78 | CCR1 (0.45) | CCR1CCR5CCR8CYP1A2PIK3CB | |
| SCHEMBL1269052 | 0.78 | APP (0.43) | APPPIK3CBCHRNA7PIK3CAMTOR | |
| SCHEMBL3481120 | 0.78 | PIK3CB (0.49) | APPPIK3CBCHRNA7PIK3CAMTOR | |
| SCHEMBL14883466 | 0.78 | APP (0.46) | APPPIK3CBCHRNA7KDM4EPIK3CA | |
| SCHEMBL857319 | 0.78 | HSD17B10 (0.44) | APPPIK3CBCHRNA7KDM4EPIK3CA | |
| SCHEMBL21886203 | 0.78 | CCR1 (0.45) | CCR1CCR5CCR8CYP1A2PIK3CB | |
| SCHEMBL21704227 | 0.76 | CCR1 (0.42) | CCR1CCR5CCR8CYP1A2KDM4E | |
| SCHEMBL11922142 | 0.76 | APP (0.41) | APPPIK3CBCHRNA7PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024105364-A1 | HETEROCYCLIC INHIBITORS OF CDC-LIKE KINASES | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| EP-3628044-B1 | PYRROLO[2,3-C]PYRIDINES AND RELATED ANALOGS AS LSD-1 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| US-20220220104-A1 | PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20220088043-A1 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2022-03-24 | — | — | US | disclosed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| EP-3950685-A1 | PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF | Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-20110009364-A1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| WO-2010050445-A1 | BICYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2010-05-06 | — | — | WO | disclosed |
| US-7652137-B2 | Substitued azaindoline intermediate for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles; pharmaceutical intermediates | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7605168-B2 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PLEXXIKON, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| WO-2009112678-A2 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | WO | disclosed |
| WO-2008132162-A1 | 3- (SULPHONYLAMINO) -PHENYL-2 -HYDROXY-ETHYLAMINO DERIVATIVES USEFUL AS BETA-AGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-06 | — | — | WO | disclosed |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008050101-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007007040-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CCR1 4485/4885CCR5 4295/4885CCR8 4585/4885 |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | CCR1 1131/4885CCR5 1116/4885CCR8 2481/4885 |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | HK1, GCKR, GCK | CCR1 1063/4885CCR5 2024/4885CCR8 3384/4885 |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | CCR1 585/4885CCR5 966/4885CCR8 62/4885 |
| US-20220088043-A1 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS | TOP2B, TOP2A, TOP1 | CCR1 3931/4885CCR5 4118/4885CCR8 3468/4885 |
| US-20110009364-A1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | ZYX, XDH, ZFX | CCR1 605/4885CCR5 1519/4885CCR8 895/4885 |
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | MCL1, BCL2A1, BCL2L1 | CCR1 1575/4885CCR5 2595/4885CCR8 2969/4885 |
| US-20220220104-A1 | PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF | RET, BRAF, RAF1 | CCR1 2539/4885CCR5 1392/4885CCR8 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.